Details of the Drug Combinations

General Information of This Drug (ID: DM2KITF)

Drug Name

LY335979 DM2KITF

Synonyms

Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Discontinued in Phase 3	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

13 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AST-487 + LY335979	DCOA9YU	AST-487	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Docetaxel + LY335979	DCCRNZ2	Docetaxel	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
LY335979 + Panobinostat	DCOJ3WO	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
LY335979 + Idarubicin	DCEAQ45	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
MLN1117 + LY335979	DCF02YB	MLN1117	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PF-05212384 + LY335979	DCLOVFH	PF-05212384	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PHA-793887 + LY335979	DCMI6NI	PHA-793887	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Plicamycin + LY335979	DC8K20L	Plicamycin	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Romidepsin + LY335979	DCOVA6D	Romidepsin	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Taxol + LY335979	DC4ZKX4	Taxol	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Vinorelbine + LY335979	DCDMJGF	Vinorelbine	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[3]
VX-680 + LY335979	DCGUG9T	VX-680	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Ym155 + LY335979	DC5GUE9	Ym155	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DrugCom(s)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005159)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.